Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$107.45 +0.92 (+0.86%)
As of 06/30/2025 03:58 PM Eastern

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$106.25
$107.53
50-Day Range
$94.96
$107.45
52-Week Range
$71.88
$108.57
Volume
7.01 million shs
Average Volume
6.60 million shs
Market Capitalization
$158.97 billion
P/E Ratio
78.43
Dividend Yield
N/A
Price Target
$116.09
Consensus Rating
Buy

Company Overview

Boston Scientific Corporation, founded in 1979 and headquartered in Marlborough, Massachusetts, is a global developer, manufacturer, and marketer of medical devices designed to diagnose and treat a broad range of cardiovascular, respiratory, digestive and urological conditions. Over more than four decades, the company has built a reputation for innovation in minimally invasive therapies, enabling physicians and healthcare providers to deliver advanced care to patients around the world.

The company’s core product portfolio spans interventional cardiology, electrophysiology, peripheral interventions, endoscopy, urology and neuromodulation. In cardiovascular care, Boston Scientific offers drug-eluting stents, pacemakers and implantable cardioverter-defibrillators, along with diagnostic catheters and balloons for angioplasty. Its endoscopy range includes advanced imaging systems and biopsy tools for gastrointestinal procedures, while urology products feature lithotripsy devices and implantable stents for the treatment of urinary strictures. The neuromodulation business provides spinal cord stimulation systems for chronic pain management, as well as implants for movement and pelvic health disorders.

With operations in more than 130 countries, Boston Scientific serves hospitals, outpatient clinics and physician offices across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company maintains research and development centers in North America and Europe, with additional manufacturing facilities in Ireland, Costa Rica and India. This global footprint supports collaboration with leading clinicians and academic institutions to advance clinical research and product innovation.

Leadership at Boston Scientific is headed by President and Chief Executive Officer Robert S. Ford, who brings extensive industry experience and a focus on strategic growth and operational excellence. The company’s commitment to cutting-edge technology is evidenced by a series of strategic acquisitions over the years, which have expanded its therapeutic offerings and strengthened its position in key markets. Through continual investment in R&D and a drive to improve patient outcomes, Boston Scientific aims to deliver enduring value to healthcare professionals and patients worldwide.

AI Generated. May Contain Errors.

Boston Scientific Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 83% of companies evaluated by MarketBeat, and ranked 188th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 21 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 13.33% in the coming year, from $2.85 to $3.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 78.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 78.43, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.44.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    1.19% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.19% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Boston Scientific has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 65 news articles for Boston Scientific this week, compared to 28 articles on an average week.
  • Search Interest

    41 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.
  • MarketBeat Follows

    Only 11 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,406,693.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Gold Shock (insane new prediction)
World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "financially stressed." Over 2.2 million Americans saw their credit score fall 100 points from late payments. And everything from Red Lobster to Walmart to CVS is closing stores. What happens next will be even worse, but could hand savvy gold investors huge gains. There IS a right way to buy gold.
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $89.32 at the beginning of the year. Since then, BSX shares have increased by 20.3% and is now trading at $107.45.
View the best growth stocks for 2025 here
.

Boston Scientific Corporation (NYSE:BSX) announced its quarterly earnings results on Wednesday, April, 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific's revenue for the quarter was up 20.9% on a year-over-year basis.
Read the conference call transcript
.

Boston Scientific subsidiaries include these companies: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and others.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
4/23/2025
Today
7/01/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:BSX
Employees
53,000
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$116.09
High Stock Price Target
$130.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+8.0%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
24 Analysts

Profitability

Trailing P/E Ratio
78.43
Forward P/E Ratio
37.70
P/E Growth
2.75
Net Income
$1.85 billion
Pretax Margin
14.12%

Debt

Sales & Book Value

Annual Sales
$16.75 billion
Cash Flow
$3.68 per share
Price / Cash Flow
29.18
Book Value
$14.93 per share
Price / Book
7.20

Miscellaneous

Outstanding Shares
1,479,450,000
Free Float
1,472,049,000
Market Cap
$158.97 billion
Optionable
Optionable
Beta
0.68

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NYSE:BSX) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners